Lenvatinib (formerly E-7080, ER-203492-00; trade name Lenvima among others) is a potent and orally bioavailable multi-targeted kinase [VEGFR2(KDR)/VEGFR3(Flt-4)] inhibitor with potential antitumor activity. 0

Motesanib, the diphosphate salt of Motesanib (formerly AMG706) is an ATP-competitive and orally bioavailable inhibitor of vascular endothelial growth factor (VEGFR1/2/3) with potential antitumor activity.

ZM323881 HCl (ZM-323881 Hydrochloride) is a novel, potent and selective tyrosine kinase VEGFR2 inhibitor with potential antitumor activity.

Pazopanib HCl (formerly GW786034 HCl; GW-786034; trade name Votrient) is a novel and potent multi-targeted receptor tyrosine kinase inhibitor with potential anticancer activity.

OSI-930 is an orally bioavailable, potent and selective inhibitor of multi-kinase (Kit, KDR and CSF-1R) with potential antineoplastic activity.

Lucitanib (formerly E3810; AL3810; E-3810) is a novel and potent dual VEGFR and FGFR inhibitor with anticancer effects.

Altiratinib (also known as DCC-2701 and DP-5164) is an orally active, highly potent and selective multi-kinase inhibitor with IC50 values of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3.

SKLB610 is a novel multi-targeted kinase inhibitor with more potent inhibition of VEGFR2.

Tanshinone IIA (Tan IIA; Dan Shen ketone), derived from phenanthrene-quinone, which is isolated from Salvia miltiorrhiza BUNGE.

Vatalanib ((PTK787 or ZK 222584, cpg-79787) is a novel, potent and orally bioavailable inhibitor of VEGFR2/KDR with IC50 of 37 nM in a cell-free assay, it is less potent against VEGFR1/Flt-1, and is 18-fold against VEGFR3/Flt-4.